Mobilization and Exercise Intervention for Patients With Multiple Myeloma: Clinical Practice Guidelines Endorsed by the Canadian Physiotherapy Association.
Deepa Jeevanantham, Venkadesan Rajendran, Zachary McGillis and 3 others
PMID 32975563WHAT IT FOUND
Physical therapists can mobilize multiple myeloma patients with low blood counts if they monitor for adverse signs.
Exercise is safe with platelet counts above 10,000/μL using gentle movements, and hemoglobin levels below 8 g/dL require close vital sign checks rather than withholding therapy.
Key findings
01Patients with hemoglobin levels between 7 and 8 g/dL can tolerate physiotherapy if monitored for adverse events, though intervention is generally contraindicated below 8 g/dL.
02For platelet counts between 10,000 and 20,000/μL, gentle range of motion and strength training without resistance are recommended, while counts below 10,000/μL limit activity to essential ambulation.
03Bony lesions are not absolute contraindications to physical therapy, but exercises must avoid twisting, forward bending, and overhead reaching to prevent vertebral fractures.
STILL TO COME
How it was doneWhat they foundWhat it means for PTs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
The evidence base is weak, relying heavily on expert opinion and a small number of included articles (15). The consensus panel was small (9 PTs and 9 patients), which may limit generalizability. Many recommendations are based on extrapolation from mixed hematological cancer samples rather than multiple myeloma-specific trials. The guidelines note a lack of specific research on exercise during the pre-transplant phase.
Declared interests
Funding was provided by the Northern Ontario Academic Medicine Association. No other conflicts of interest were declared in the provided text.
The easy way to misread this
Do not treat these thresholds as absolute safety guarantees or evidence of efficacy. The guidelines are based on expert consensus and limited data, not large randomized trials. Individual patient factors, such as cardiac history or specific lesion locations, require clinical judgment and physician liaison beyond these general cut-offs.